NCT02159950View on ClinicalTrials.gov

Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

July 31, 2015

Conditions
Hormone-Resistant Prostate CancerMetastatic Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate Cancer
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Sipuleucel-T

Given IV

DRUG

Tasquinimod

Given PO

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

Active Biotech AB
All Listed Sponsors
collaborator

Active Biotech AB

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER

NCT02159950 - Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter